Overview:

**COVID-19 RELATION**
Bafilomycin A is a macrolide antibiotic and a highly potent V-ATPase inhibitor. It has been well researched for its role as an inhibitor of the vascular proton ATPases and has been administered to demonstrate the requirement of low endosomal pH for viral uncoating. Bafilomycin A has been actively studied for its role against viruses like influenza A and hepatitis C. Scientists are studying clinical implications of using Bafilomycin A1 against the SARS-CoV-2 virus as it has been documented that the Nsp6 and M proteins of SARS-CoV-2 interact with the V1-ATPase subunits.**

A vacuolar H+-ATPase inhibitor, IC₅₀ = 0.6-1.5 nM in bovine chromaffin granules (1). Highly selective for V-ATPase over F-ATPases and P-ATPase. Inhibits autophagy by preventing maturation of autophagic vacuoles via inhibition of fusion between autophagosomes and lysosomes (2). Inhibits bone resorption in various models (3). An extremely useful tool for exploring physiological processes regulated by V-ATPase (4).

References:

1. S Gagliardi et al. Curr. Med. Chem. 1999 6:1197

2. A Yamamoto et al. Cell Struct. Funct. 1998 23:33

3. AV Neutzsky-Wulff et al. BMC Musculoskelet. Disord. 2010 11:109

4. T Yoshimori et al. J. Biol. Chem. 2015 290:8039